Table 4.
Cardiac findings in patients with symptomatic ATTRv Glu89Gln amyloidosis and predominantly cardiac or mixed phenotype
| Overall (n = 59) |
Bulgaria (n = 43) |
Italy (n = 11) |
Other countries (n = 5) |
|
|---|---|---|---|---|
| Echocardiogram | ||||
| LV septal thickness, n | 51 | 41 | 7 | 3 |
| mm, mean (SD) | 17.02 (3.11) | 17.02 (2.72) | 18.29 (4.92) | 14.00 (1.73) |
| LV diastolic thickness, n | 49 | 41 | 5 | 3 |
| mm, mean (SD) | 43.69 (5.40) | 44.07 (5.52) | 41.40 (5.77) | 42.33 (2.52) |
| LV posterior wall, n | 50 | 41 | 6 | 3 |
| mm, mean (SD) | 16.60 (3.05) | 16.78 (2.64) | 16.83 (5.42) | 13.67 (1.15) |
| LV ejection fraction, n | 51 | 41 | 7 | 3 |
| %, mean (SD) | 56.04 (13.73) | 56.93 (13.57) | 49.71 (16.74) | 58.67 (4.73) |
| Cardiac biomarkers | ||||
| NT-proBNP, n | 9 | 3 | 4 | 2 |
| pg/ml, mean (SD) | 5143.85 (6377.08) | 4119.21 (4328.82) | 7820.93 (8658.64) | 1326.65 (1409.05) |
ATTRv Glu89Gln amyloidosis ATTRv amyloidosis associated with the Glu89Gln variant, LV left ventricular, NT-proBNP N-terminal pro-B-type natriuretic peptide, SD standard deviation, THAOS Transthyretin Amyloidosis Outcomes Survey (data cutoff, January 6, 2020)